Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 29Carcinoma, Hepatocellular 2Thyroid Neoplasms 1Renal Insufficiency 1Prostate Adenocarcinoma 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Melanoma 1Carcinoma, Adenoid Cystic 1

Interventions

Sorafenib 10Magnetic Resonance Spectroscopy 10trametinib 8lenvatinib 8dabrafenib 7pembrolizumab 6Nivolumab 6Iodine-131 6Everolimus 6Sunitinib 5Paclitaxel 5vandetanib 4apatinib 4Thyrotropin Alfa 4Doxorubicin 4selpercatinib 3anlotinib 3Specimen Handling 3Radiotherapy 3Ipilimumab 3Iodine-124 3Fluorodeoxyglucose F18 3Cisplatin 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3tislelizumab 2tipifarnib 2surufatinib 2spartalizumab 2pazopanib 2omipalisib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Thyroid Neoplasms × gallium 68 PSMA-11 × Clear all
NCT03463889 2021-06-29

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

University of California, San Francisco

Phase 2 Terminated
12 enrolled 10 charts
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡